155 related articles for article (PubMed ID: 19457248)
1. MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome.
Nielsen JM; Pohl C; Polman CH; Barkhof F; Freedman MS; Edan G; Miller DH; Bauer L; Sandbrink R; Kappos L; Uitdehaag BM
BMC Neurol; 2009 May; 9():19. PubMed ID: 19457248
[TBL] [Abstract][Full Text] [Related]
2. Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b.
Polman C; Kappos L; Freedman MS; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Selmaj K; Uitdehaag BM; Dahms S; Bauer L; Pohl C; Sandbrink R;
J Neurol; 2008 Apr; 255(4):480-7. PubMed ID: 18004635
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.
Moraal B; Pohl C; Uitdehaag BM; Polman CH; Edan G; Freedman MS; Hartung HP; Kappos L; Miller DH; Montalban X; Lanius V; Sandbrink R; Barkhof F
Arch Neurol; 2009 Nov; 66(11):1345-52. PubMed ID: 19901165
[TBL] [Abstract][Full Text] [Related]
4. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.
Kappos L; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Radü EW; Bauer L; Dahms S; Lanius V; Pohl C; Sandbrink R;
Lancet; 2007 Aug; 370(9585):389-97. PubMed ID: 17679016
[TBL] [Abstract][Full Text] [Related]
5. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
Kappos L; Polman CH; Freedman MS; Edan G; Hartung HP; Miller DH; Montalban X; Barkhof F; Bauer L; Jakobs P; Pohl C; Sandbrink R
Neurology; 2006 Oct; 67(7):1242-9. PubMed ID: 16914693
[TBL] [Abstract][Full Text] [Related]
6. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Kappos L; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Radü EW; Metzig C; Bauer L; Lanius V; Sandbrink R; Pohl C;
Lancet Neurol; 2009 Nov; 8(11):987-97. PubMed ID: 19748319
[TBL] [Abstract][Full Text] [Related]
7. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.
O'Connor P;
Clin Ther; 2003 Nov; 25(11):2865-74. PubMed ID: 14693310
[TBL] [Abstract][Full Text] [Related]
8. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
9. Classification of patients with a clinically isolated syndrome based on signs and symptoms is supported by magnetic resonance imaging results.
Nielsen JM; Moraal B; Polman CH; Poppe P; de Vos M; Freedman MS; Kappos L; Barkhof F; Bauer L; Pohl C; Sandbrink R; Hartung HP; Uitdehaag BM
Mult Scler; 2007 Jul; 13(6):717-21. PubMed ID: 17613598
[TBL] [Abstract][Full Text] [Related]
10. Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.
Barkhof F; Polman CH; Radue EW; Kappos L; Freedman MS; Edan G; Hartung HP; Miller DH; Montalbán X; Poppe P; de Vos M; Lasri F; Bauer L; Dahms S; Wagner K; Pohl C; Sandbrink R
Arch Neurol; 2007 Sep; 64(9):1292-8. PubMed ID: 17846268
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria.
O'Connor P; Kinkel RP; Kremenchutzky M
Mult Scler; 2009 Jun; 15(6):728-34. PubMed ID: 19482863
[TBL] [Abstract][Full Text] [Related]
12. Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study.
Freedman MS; De Stefano N; Barkhof F; Polman CH; Comi G; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Lehr L; Stubinski B; Jack DL; Kappos L
J Neurol; 2014 Mar; 261(3):490-9. PubMed ID: 24413638
[TBL] [Abstract][Full Text] [Related]
13. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.
Barkhof F; Rocca M; Francis G; Van Waesberghe JH; Uitdehaag BM; Hommes OR; Hartung HP; Durelli L; Edan G; Fernández O; Seeldrayers P; Sørensen P; Margrie S; Rovaris M; Comi G; Filippi M;
Ann Neurol; 2003 Jun; 53(6):718-24. PubMed ID: 12783417
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L
Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
[TBL] [Abstract][Full Text] [Related]
15. Interferon-beta-1b: in newly emerging multiple sclerosis.
McKeage K
CNS Drugs; 2008; 22(9):787-92. PubMed ID: 18698876
[TBL] [Abstract][Full Text] [Related]
16. Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
Cree BAC; Bowen JD; Hartung HP; Vermersch P; Hughes B; Damian D; Hyvert Y; Dangond F; Galazka A; Grosso M; Jones DL; Leist TP
Mult Scler Relat Disord; 2021 Apr; 49():102695. PubMed ID: 33578191
[TBL] [Abstract][Full Text] [Related]
17. Oligoclonal bands and MRI in clinically isolated syndromes: predicting conversion time to multiple sclerosis.
J Neurol; 2010 Jul; 257(7):1188-91. PubMed ID: 20157721
[TBL] [Abstract][Full Text] [Related]
18. Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis.
Sombekke MH; Wattjes MP; Balk LJ; Nielsen JM; Vrenken H; Uitdehaag BM; Polman CH; Barkhof F
Neurology; 2013 Jan; 80(1):69-75. PubMed ID: 23243070
[TBL] [Abstract][Full Text] [Related]
19. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis.
Soilu-Hänninen M; Aivo J; Lindström BM; Elovaara I; Sumelahti ML; Färkkilä M; Tienari P; Atula S; Sarasoja T; Herrala L; Keskinarkaus I; Kruger J; Kallio T; Rocca MA; Filippi M
J Neurol Neurosurg Psychiatry; 2012 May; 83(5):565-71. PubMed ID: 22362918
[TBL] [Abstract][Full Text] [Related]
20. Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis.
Penner IK; Stemper B; Calabrese P; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Pleimes D; Lanius V; Pohl C; Kappos L; Sandbrink R
Mult Scler; 2012 Oct; 18(10):1466-71. PubMed ID: 22492127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
